FDA extends Zinplava review, requests more data

Merck & Co. Inc. (NYSE:MRK) said FDA extended its review of a BLA for Zinplava bezlotoxumab (

Read the full 173 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE